NCT01654822View on ClinicalTrials.gov

AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

January 31, 2013

Conditions
Genital Human Papilloma Virus Infection
Interventions
DRUG

topical application cervical spray

one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix

DRUG

topical spray on the cervix

one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix

PROCEDURE

cervical swab with Cervex-Brush-Combi at T0

PROCEDURE

cervical swab with Cervex-Brush-Combi at T1

PROCEDURE

cervical swab with Cervex-Brush-Combi at T0

PROCEDURE

cervical swab with Cervex-Brush-Combi at T1

Trial Locations (1)

2020

Labo Riatol, Antwerp

Sponsors
All Listed Sponsors
lead

Cesa Projects International

INDUSTRY

NCT01654822 - AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections | Biotech Hunter | Biotech Hunter